Education
About Us
Working with TipRanks
Follow Us
Hemogenyx Pharmaceuticals Plc (GB:HEMO)
:HEMO
RESEARCH TOOLSreports
HEMO Stock Chart & Stats
Day’s Range― - ―
52-Week Range149.62p - 1,199.60p
Previous CloseN/A
Volume114.00
Average Volume (3M)25.70K
Market Cap
£7.04M
Enterprise Value5.21B
Total Cash (Recent Filing)£159.26K
Total Debt (Recent Filing)£2.62M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Sep 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding4,593,539
10 Day Avg. Volume30,624
30 Day Avg. Volume25,705
Financial Highlights & Ratios
PEG Ratio21.94
Price to Book (P/B)1.59K
Price to Sales (P/S)0.00
P/FCF Ratio-1.56K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
HemoGenyx Pharmaceuticals Plc News
PremiumCompany Announcements
Hemogenyx Pharmaceuticals Gains FDA Clearance for Pediatric Trial Expansion
PremiumCompany Announcements
Hemogenyx Pharmaceuticals Secures Funding for Clinical Trials
PremiumCompany Announcements
Hemogenyx Advances CAR-T Therapy with Successful Second Patient TreatmentPremiumCompany Announcements
Hemogenyx Pharmaceuticals Announces Total Voting Rights Update
PremiumCompany Announcements
Hemogenyx Pharmaceuticals Announces Successful AGM Resolutions
PremiumCompany Announcements
Hemogenyx Expands HG-CT-1 Trial to Pediatric Patients
PremiumCompany Announcements
Hemogenyx Pharmaceuticals Corrects AGM Notice ErrorPremiumCompany Announcements
Hemogenyx Pharmaceuticals Secures Funding for Phase 1 Clinical TrialsOptions Prices
Currently, No data available
---
Ownership Overview
7.70%
Insiders
―
Mutual Funds
― Other Institutional Investors
92.30% Public Companies and
Individual Investors
HEMO FAQ
What was Hemogenyx Pharmaceuticals Plc’s price range in the past 12 months?
Hemogenyx Pharmaceuticals Plc lowest share price was 149.62p and its highest was 1199.60p in the past 12 months.
What is Hemogenyx Pharmaceuticals Plc’s market cap?
Hemogenyx Pharmaceuticals Plc’s market cap is £7.04M.
When is Hemogenyx Pharmaceuticals Plc’s upcoming earnings report date?
Hemogenyx Pharmaceuticals Plc’s upcoming earnings report date is Sep 25, 2025 which is in 86 days.
How were Hemogenyx Pharmaceuticals Plc’s earnings last quarter?
Hemogenyx Pharmaceuticals Plc released its earnings results on Apr 28, 2025. The company reported -0.801p earnings per share for the quarter, missing the consensus estimate of N/A by -0.801p.
Is Hemogenyx Pharmaceuticals Plc overvalued?
According to Wall Street analysts Hemogenyx Pharmaceuticals Plc’s price is currently Overvalued.
Does Hemogenyx Pharmaceuticals Plc pay dividends?
Hemogenyx Pharmaceuticals Plc does not currently pay dividends.
What is Hemogenyx Pharmaceuticals Plc’s EPS estimate?
Hemogenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hemogenyx Pharmaceuticals Plc have?
Hemogenyx Pharmaceuticals Plc has 4,593,539 shares outstanding.
What happened to Hemogenyx Pharmaceuticals Plc’s price movement after its last earnings report?
Hemogenyx Pharmaceuticals Plc reported an EPS of -0.801p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.546%.
Which hedge fund is a major shareholder of Hemogenyx Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in GB:HEMO
Company Description
Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
Technical Analysis
ImmuPharma
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―